Organization | Polish Adult Leukemia Group

Polish Adult Leukemia Group Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2014

NCT02072811

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

dr hab. n. med. Agnieszka Wierzbowska | PALG | Polish Adult Leukemia Group | Polish Adult Leukemia Group, Gliwice, Poland

Active Ingredients

Drugs in Phase 3 Trials (7)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

mitoxantrone (novantrone) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 7